First for Women on MSN3mon
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.
Nasdaq1mon
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...
Reuters8d
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
Yahoo1mon
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it. Since Ozempic blasted onto the stage in 2017 with ...
Monthly Prescribing Reference1mon
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...
Nasdaq1mon
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...
Reuters8d
Novo Nordisk says it has not yet posted details about new CagriSema trial
Japanese trading house Marubeni said on Wednesday it is aiming for a net profit of more than 620 billion yen ($4 billion) in fiscal year 2027/2028, with shareholder returns of 40% which should ...
Business Insider1mon
Weight loss seen with Novo’s CagriSema weaker than expected, says BofA
BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated comp ...
Morningstar1mon
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment
Novo Nordisk disclosed top-line data from the phase 3 Redefine 1 study showing 20.4% placebo-adjusted weight loss for obesity drug candidate CagriSema after 68 weeks of treatment, among patients ...
MarketWatch1mon
Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...
Hosted on MSN1mon
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...
Yahoo Finance1mon
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components ...